Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 19/20 | 0.62 |
| ▸ | ACE | P12821 | 10/20 | 0.62 |
| ▸ | EMG1 | Q92979 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20358091 | 1.00 | MME (0.62) | MMEACEEMG1 | |
| SCHEMBL16008912 | 0.84 | MME (0.66) | MMEACEEMG1 | |
| SCHEMBL16011785 | 0.84 | MME (0.66) | MMEACEEMG1 | |
| SCHEMBL16009004 | 0.80 | MME (0.78) | MMEACE | |
| SCHEMBL14890447 | 0.78 | MME (1.00) | MMEACE | |
| SCHEMBL18597868 | 0.78 | MME (1.00) | MMEACE | |
| SCHEMBL16008092 | 0.75 | MME (0.77) | MMEACE | |
| SCHEMBL16008239 | 0.75 | MME (0.80) | MMEACE | |
| SCHEMBL16008640 | 0.75 | MME (0.80) | MMEACE | |
| SCHEMBL18724654 | 0.75 | MME (0.61) | MMEACEEMG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194718-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885ACE 3/4885EMG1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.